Response to Grech et al.: FLOUX-PMS study sample considerations

Jop P Mostert¹, Jacques De Keyser^{2

3

4}

Affiliations

¹ Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
² Department of Neurology, UZ Brussel, Brussel, Belgium.
³ Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
⁴ Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Comment

Jop P Mostert et al. Mult Scler. 2019 Nov.

. 2019 Nov;25(13):1820-1821.

doi: 10.1177/1352458519876027. Epub 2019 Sep 20.

Jop P Mostert¹, Jacques De Keyser^{2

3

4}

¹ Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
² Department of Neurology, UZ Brussel, Brussel, Belgium.
³ Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
⁴ Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

No abstract available

Comment on

Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Cambron M, Mostert J, D'Hooghe M, Nagels G, Willekens B, Debruyne J, Algoed L, Verhagen W, Hupperts R, Heersema D, De Keyser J; FLUOX-PMS Study Group. Cambron M, et al. Mult Scler. 2019 Nov;25(13):1728-1735. doi: 10.1177/1352458519843051. Epub 2019 Jun 20. Mult Scler. 2019. PMID: 31218911
Letter to the editor: FLOUX-PMS study sample considerations.
Grech LB, Butler E, Stuckey S, Hester R. Grech LB, et al. Mult Scler. 2019 Nov;25(13):1819-1820. doi: 10.1177/1352458519876025. Epub 2019 Sep 20. Mult Scler. 2019. PMID: 31538537 No abstract available.